JB Chemicals & Pharmaceuticals Ltd - 506943 - Audio Recording Of Earnings Conference Call
Audio recording of the Earnings Conference Call - Q1 FY 2021-2214-08-2021
14-08-2021
Earnings Call for Q1FY22 of J B Chemicals & Pharmaceuticals
Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.13-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of duplicate share certificate13-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Newspaper Cutting Of Extract Of Consolidated Financial Results For Quarter Ended On June 30, 2021
Newspaper cutting of extract of consolidated financial results for quarter ended on June 30, 202113-08-2021
JB Chemicals & Pharma logs Rs 119 cr net profit in Q1
The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE13-08-2021
Q1FY22 Result Announced for J B Chemicals & Pharmaceuticals Ltd.
Financial Highlights: For the first quarter ended 30th June 2021, the Company recorded revenue of Rs. 606 crores as compared to Rs. 522.3 crores, registering growth of 16 % over the corresponding quarter ended 30th June, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 5 % to Rs. 163.7 crores as compared to Rs. 155.4 crores. EBITDA margin for the quarter was at 27 % as compared to 29.8 %. Profit after Tax was flat at Rs. 118.9 crores as compared to Rs. 119.4 crores. The organization continues to perform well with revenue momentum continuing to remain strong Highest ever quarterly revenue recorded during the first quarter of FY21, despite lockdowns in key markets and supply chain challenges Domestic Formulations business records 39 % growth while the International business revenue was largely flat as compared to Q1 FY21 As per MAT June 2021 IQVIA data, Domestic Formulations maintains secular outperformance compared to industry growth rates, driven by strength in chronic segments and expanding prescriber coverage Uncertainty in view of the second wave of COVID-19 impacted growth in certain geographies in the international market during the quarter Gross Margin profile continues to remain healthy at 64 % aided by good product mix EBITDA margin remains strong despite cost base returning to normal level of operations during Q1 FY 22 Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry. Our new GoTo-Market(GTM) model has been implemented and early signs are encouraging, which is reflected in the strong performance of flagship brands and new launches. While demand trends in international business continue to be volatile (given the COVID situation); our key markets like US, S Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival. We expect the performance to improve in select pockets of our international business. Going forward, our priority continues to build on cost efficiency measures while maintaining the same growth momentum” Result PDF13-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation12-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on unaudited consolidated financial results for the quarter ended on June 30, 2021.12-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Unaudited Financial Results For The Quarter Ended June 30, 2021
Unaudited Financial Results for the quarter ended June 30, 202112-08-2021
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended June 30, 2021
Outcome of meeting of Board of Directors - Unaudited Financial Results for the quarter ended June 30, 202112-08-2021